

AACC 2020 CLFS Recommendations

| Code | Code Description | Crosswalks and Rationale | 2019 NLA |
|---|--|--|-----------------|
| New - Molecular Pathology | | | |
| 813X1 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; full gene sequence | Crosswalk to 81317 for the full gene sequencing of PMS2. PALB2 has 13 exons and 1186 amino acids. In comparison, PMS2 has 15 exons and 873 amino acids. | \$676.50 |
| 813X2 | PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) gene analysis; known familial variant | Crosswalk to 81318 PMS2 for targeted analysis of a known familial variant. | \$331.00 |
| 8XX01 | PIK3CA (phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha) (eg, colorectal and breast cancer) gene analysis, targeted sequence analysis (eg, exons 7, 9, and 20) | Crosswalk to 81314 for the target analysis of select exons of PDGFRA. | \$329.51 |
| 8XX0X | Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities | Crosswalk to 81229 for the genome-wide microarray analysis for constitutional conditions. | \$1,160.00 |
| Reconsider - Molecular Pathology | | | |
| 81163 | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis | Crosswalk to CPT 81408 for the full gene sequencing of DMD. DMD has 79 exons and 3685 amino acids. In comparison, BRCA1 has 29 exons and 1184 amino acids and BRCA2 has 27 exons and 3418 acids. | \$2,000 |
| 81165 | BRCA1 (BRCA1, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis | Crosswalk to CPT 81408. The methodology and amount of DNA sequenced is comparable to half that of the sequencing of the large gene DMD. 81408/NLA. | \$1,000 |